GURU.Markets stock price, segment price, and overall market index valuation
The company's share price MorphoSys AG
The historical chart of MorphoSys, a German biotech company, reflected progress in the development of antibodies and its key blood cancer drug. Its history culminated in its acquisition by Novartis in 2024.
Share prices of companies in the market segment - Cancer cure
MorphoSys is a German biopharmaceutical company pioneering the development of therapeutic antibodies for the treatment of cancer and autoimmune diseases. We categorize it as a "Cancer Treatment" company. The chart below shows how investors view the biotech sector in Europe.
Broad Market Index - GURU.Markets
MorphoSys is a German biotech company developing antibody-based drugs for cancer treatment. As a major European player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with MorphoSys' performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
MOR - Daily change in the company's share price MorphoSys AG
For MorphoSys AG, an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Cancer cure
MorphoSys is a German biopharmaceutical company that was acquired by Novartis. The deal was aimed at gaining access to a promising cancer drug. The chart below illustrates the volatility in the biotech sector, where successful developments often lead to acquisitions.
Daily change in the price of a broad market stock, index - GURU.Markets
MorphoSys is a German biotech company developing cancer treatments. Its US-listed shares bring the dynamism of the European biotech sector to the market. These international factors complicate the overall market volatility picture.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization MorphoSys AG
For MorphoSys AG, year-over-year performance is a story of transformation. Its market capitalization change over the past 12 months reflects both sales of its oncology drug and, more importantly, its recent acquisition by Novartis, which was interested in its promising myelofibrosis drug, a key event.
Annual dynamics of market capitalization of the market segment - Cancer cure
MorphoSys is a German biotech company. Its expected acquisition by Novartis is a key factor. Its stock price reflects not so much the results of its R&D as the terms of this major deal, making its performance unique in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
MorphoSys, a German biopharmaceutical company with a rich history and successful commercial oncology products, is a mature biotech player. Its year-over-year market capitalization reflects both sales growth of existing drugs and expectations for new developments.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization MorphoSys AG
MorphoSys is a German biotech company. Its monthly performance was extremely volatile, dependent on clinical trial news. The chart shows sharp movements that culminated in a spike following the announcement of its acquisition by pharmaceutical giant Novartis.
Monthly dynamics of market capitalization of the market segment - Cancer cure
MorphoSys AG is a German biopharmaceutical company specializing in the development and commercialization of therapeutic antibodies for the treatment of cancer and autoimmune diseases. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess how its proprietary technologies and development pipeline, including approved drugs, impact its valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
MorphoSys is a German biotech company. Its NASDAQ stock price is driven by news of clinical trials and partnerships. The chart shows the high volatility typical of biotechs, whose value is a bet on the success of future drugs, independent of overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization MorphoSys AG
MorphoSys, a German biotech company developing antibody-based drugs, exhibits high volatility. Weekly stock performance is driven by news about clinical trials and the commercial success of its oncology drugs, mirroring the dynamics of the European biotech industry.
Weekly dynamics of market capitalization of the market segment - Cancer cure
MorphoSys shares, like those of the entire oncology biotech sector, are driven by industry-wide news and sentiment. Breakthroughs in blood cancer treatments or changes in FDA policy could boost the entire industry. The chart shows how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
MorphoSys is a German biotech company. Its shares follow the rhythm of development news. The chart will show how MOR's dynamics are independent of general market fluctuations, moving on its own unique scientific and commercial news.
Market capitalization of the company, segment and market as a whole
MOR - Market capitalization of the company MorphoSys AG
The MorphoSys chart is the financial history of a German biotech pioneer. Its market capitalization reflects not only its proprietary blood cancer drug but also its antibody platform, which is used by many pharmaceutical companies. Its performance is a barometer of its commercial success and progress in drug development.
MOR - Share of the company's market capitalization MorphoSys AG within the market segment - Cancer cure
MorphoSys AG is a German biopharmaceutical company focused on oncology and autoimmune diseases. Its market capitalization within the European biotech sector reflects its status as a leader in antibody development. The company's strength is the result of its successful drug launches and promising development pipeline.
Market capitalization of the market segment - Cancer cure
MorphoSys is a German biotech company specializing in the development of antibody-based drugs. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect investor hopes for breakthroughs in targeted cancer therapy.
Market capitalization of all companies included in a broad market index - GURU.Markets
MorphoSys is a German biotech company, a pioneer in the field of therapeutic antibodies. Its market capitalization chart tells the story of long-term investments in science. Its dynamics reflect both the success of its own developments and the value of its technology platform used by its partners.
Book value capitalization of the company, segment and market as a whole
MOR - Book value capitalization of the company MorphoSys AG
The book value of MorphoSys, a German biotech company, is the sum of its equity, laboratories, and drug rights. The chart below tells the story of its transformation. Its growth reflects both development successes and major acquisitions that added new assets to the balance sheet.
MOR - Share of the company's book capitalization MorphoSys AG within the market segment - Cancer cure
MorphoSys is a German biotech company developing antibodies for cancer treatment. It has both R&D and manufacturing capabilities. This chart shows how its physical infrastructure supports the entire pipeline, from discovery to potential production of innovative drugs.
Market segment balance sheet capitalization - Cancer cure
Below you can see the overall book value of the biotech sector. Against this backdrop, MorphoSys, as a company specializing in antibodies, is moderately capital-intensive. Its presence in approved drugs and its own manufacturing facilities makes it heavier than pure R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
MorphoSys is a German biotech company, one of the oldest in Europe, focused on developing cancer antibodies. Its assets include a scientific platform, a development pipeline, and an approved drug. The company's balance sheet reflects decades of scientific expertise translated into real-world drugs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - MorphoSys AG
MorphoSys's balance sheet represents its cash and development pipeline. Its market capitalization represents the success of its new cancer drugs. The MvsBCap_Co chart shows how investors value its scientific potential compared to its tangible assets.
Market to book capitalization ratio in a market segment - Cancer cure
MorphoSys is a German biotech company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. The chart shows how the market values its scientific platform and its pipeline of commercial and developmental drugs.
Market to book capitalization ratio for the market as a whole
MorphoSys AG is a German biopharmaceutical company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. Its valuation is a combination of revenue from already approved drugs and bets on future research success. The chart provides insight into how the market balances current reality and future expectations for a mature biotech company.
Debts of the company, segment and market as a whole
MOR - Company debts MorphoSys AG
MorphoSys, a German biotech company, is using debt to finance its transformation from a technology platform to a commercial company. This chart shows how the company is raising capital to conduct late-stage clinical trials and market its oncology drugs. Debt is the fuel for commercialization.
Market segment debts - Cancer cure
MorphoSys is a long-established German biotech company that has successfully commercialized cancer treatments. This chart illustrates how a mature biotech company with sales revenue manages its finances by reinvesting profits into its extensive research and development pipeline.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio MorphoSys AG
MorphoSys is a German biotech company specializing in the development of antibodies for cancer treatment. This chart shows how the company finances its expensive research and development. It is an indicator of financial risk, which decreases as drugs progress through clinical trials and partnerships with pharmaceutical giants.
Market segment debt to market segment book capitalization - Cancer cure
MorphoSys is a German biotech company specializing in the development of antibodies for cancer treatment. The company is rapidly growing through both proprietary developments and acquisitions. The chart shows how its debt load after major acquisitions compares to the overall market capitalization of the entire oncology sector.
Debt to book value of all companies in the market
MorphoSys (MOR) is a German biopharmaceutical company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. The company has both in-house developments and partnerships. This chart shows the company's total debt burden. It allows one to assess how MorphoSys, despite its revenue, uses debt to finance its R&D programs.
P/E of the company, segment and market as a whole
P/E - MorphoSys AG
This chart shows the valuation of MorphoSys, a German biotech company. Its P/E is dependent on the success of its lead drug for treating blood cancer and the prospects of its development pipeline. The valuation also includes a premium for its antibody technology platform, which is attracting partners from major pharma companies.
P/E of the market segment - Cancer cure
This industry metric represents the average P/E for biotech companies. For MorphoSys, a German company with a commercial product, it's an important benchmark. Comparing its P/E to the industry average helps understand how investors view its commercial success and the potential of its antibody research platform.
P/E of the market as a whole
MorphoSys is a German biotech company that has developed a proprietary platform for creating therapeutic antibodies. The company has both proprietary and partner programs. This chart shows the sentiment in the biotech sector. It helps understand how the market evaluates the balance between the risks of proprietary developments and the stability of royalty and partner revenue at this mature biotech company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company MorphoSys AG
MorphoSys AG is a German biopharmaceutical company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. This chart reflects analyst expectations for the sales of its approved drug and the success of its extensive clinical development pipeline, including potential blockbusters.
%20P%2FE%20MorphoSys%20AG&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-MorphoSys-AG&v=1772513491297 "Chart of the company's future (projected) P/E MorphoSys AG")
Future (projected) P/E of the market segment - Cancer cure
MorphoSys AG is a German biotech company specializing in the development of therapeutic antibodies for the treatment of cancer and autoimmune diseases. This chart shows average expectations for the biotech sector. MorphoSys's position may indicate how investors view its scientific platform, development pipeline, and its commercial drug, Monjuvi.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772513491338 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
MorphoSys is a German biotech company specializing in the development of antibodies for cancer treatment. Its success is determined by its pipeline and partnerships. Global investor sentiment, visible in this chart, influences the sector, but clinical success is key.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513491358 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit MorphoSys AG
MorphoSys AG is a German biopharmaceutical company specializing in the development of therapeutic antibodies for the treatment of cancer and autoimmune diseases. This graph shows the long journey from a scientific platform to a commercial product. Revenue growth depends on royalties from partners and the success of its own drugs, such as the blood cancer drug Monjuvi.
Profit of companies in the market segment - Cancer cure
MorphoSys AG is a German biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer and autoimmune diseases. Profitability in this sector, as this chart shows, depends on the success of clinical trials and partnerships. For MOR, both in-house development and technology licensing are key elements of its business model.
Overall market profit
MorphoSys AG, a German biotech company specializing in developing antibodies for cancer treatment, depends on success in research and development. Its value is determined by the potential of its drugs. The economic cycle, as shown in this chart, does not affect the need for treatment, but it is important for partnerships with large pharmaceutical companies and raising capital.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company MorphoSys AG
MorphoSys is a German biotech company specializing in the development of antibodies for cancer treatment. This chart reflects analysts' forecasts for future profits, which depend on the market success of its drugs and the results of clinical trials.
%20profit%20of%20the%20company%20MorphoSys%20AG&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-MorphoSys-AG&v=1772513491448 "Graph of future (projected) profit of the company MorphoSys AG")
Future (predicted) profit of companies in the market segment - Cancer cure
MorphoSys AG is a German biotechnology company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. The company has both its own drugs and an extensive partner network. This chart shows the revenue forecast for the cancer treatment sector, reflecting expectations for the development and commercialization of therapeutic antibodies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772513491461 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
MorphoSys AG is a German biopharmaceutical company specializing in the development of antibodies for cancer treatment. Its financial performance depends on the success of its drugs and partnerships. The overall economic outlook influences its performance through market sentiment, which determines the valuations of biotech companies and the availability of capital for research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513491477 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - MorphoSys AG
MorphoSys is a German biotech company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. Its revenue consists of royalties and sales of its own drug. The chart shows how the market values its existing products, as well as the potential of its extensive clinical development pipeline.
P/S market segment - Cancer cure
MorphoSys AG is a German biotech company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. The chart shows the average revenue estimate for the biotech industry. It provides insight into how investors view its extensive development pipeline and its transition from a technology platform to a commercial company.
P/S of the market as a whole
MorphoSys AG is a German biopharmaceutical company with its own drugs and a technology platform for antibody production. The company has both commercial products and a development pipeline. This chart provides an overview of how the market perceives this mature biotech company with diversified revenue streams.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company MorphoSys AG
MorphoSys is a German biopharmaceutical company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. The chart shows the market valuation of its platform and developments. It correlates the company's value with projected future revenues from its own and partner products.
%20P%2FS%20MorphoSys%20AG&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-MorphoSys-AG&v=1772513491648 "The graph of the company's future (projected) P/S MorphoSys AG")
Future (projected) P/S of the market segment - Cancer cure
MorphoSys AG is a German biopharmaceutical company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. This chart illustrates average future sales expectations for oncology companies. It helps investors understand how highly the market values MorphoSys's scientific platform and its drug portfolio, including its own and those from partners.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772513491724 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
MorphoSys AG is a German biopharmaceutical company specializing in oncology. Its success depends on sales of its approved drug and the success of its clinical development. This graph of expectations for the US market is important, as it is a key sales market. However, MOR's fundamental value is determined by its scientific achievements.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513491772 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales MorphoSys AG
MorphoSys AG is a German biopharmaceutical company developing antibodies for cancer treatment. Unlike many biotech companies, it has approved products. Revenue in this graph is generated by direct drug sales and royalties from partners. Sales growth demonstrates the commercial success of its oncology portfolio.
Sales of companies in the market segment - Cancer cure
MorphoSys AG is a German biopharmaceutical company specializing in the development of therapeutic antibodies for the treatment of cancer and autoimmune diseases. The company has both proprietary developments and partnerships. This chart shows the sector's total revenue, reflecting the progress and commercial potential in the development of new antibody-based cancer therapies.
Overall market sales
MorphoSys AG is a German biopharmaceutical company specializing in the development of antibodies for cancer treatment. Its success depends on the approval and commercialization of its drugs. The overall economic situation, shown in this chart, influences healthcare budgets and the market's willingness to pay for innovative therapies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company MorphoSys AG
MorphoSys AG is a German biotechnology company specializing in the development of antibodies for cancer treatment. Its revenue depends on sales of approved drugs and the success of clinical trials. This chart reflects the company's expected growth in the oncology drug market and the results of its research.
%20sales%20of%20the%20company%20MorphoSys%20AG&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-MorphoSys-AG&v=1772513491996 "Schedule of future (projected) sales of the company MorphoSys AG")
Future (projected) sales of companies in the market segment - Cancer cure
MorphoSys AG is a German biotechnology company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. The company has both in-house developments and partnerships. The chart shows forecasts for the cancer treatment sector. Successful drug launches are key to MorphoSys's future.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772513492009 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
MorphoSys AG is a German biotech company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. Its success depends on the results of clinical trials and partnerships. This chart, reflecting overall economic sentiment, influences investment in the European biotech sector and M&A activity by major pharmaceutical companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513492028 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality MorphoSys AG
MorphoSys AG is a German biopharmaceutical company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. Its profitability depends on the success of its own drugs and partnerships. This chart shows how the company translates its scientific research into commercially successful drugs.
Market segment marginality - Cancer cure
MorphoSys AG is a German biopharmaceutical company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. This chart shows the average profitability in the pharmaceutical industry. The success of its commercial drugs and extensive development pipeline are key to achieving profitability above the industry average.
Market marginality as a whole
MorphoSys AG is a German biopharmaceutical company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. Its financial results are a combination of revenue from approved drugs and research expenses. This total return chart allows you to assess how a mature biotech company balances current profits with investments in the future.
Employees in the company, segment and market as a whole
Number of employees in the company MorphoSys AG
MorphoSys is a German biotech company specializing in the development of antibodies for cancer treatment. This chart shows the size of its research and development team. This staffing reflects its long-standing investment in building one of the most advanced platforms for the discovery and development of therapeutic antibodies.
Share of the company's employees MorphoSys AG within the market segment - Cancer cure
MorphoSys AG is one of Germany's oldest and most reputable biotech companies, a pioneer in the field of therapeutic antibodies. Unlike many startups, it has both R&D and commercial products. This chart shows the size of its mature organization, reflecting the balance between the scientists developing new drugs and the sales team bringing them to market.
Number of employees in the market segment - Cancer cure
MorphoSys AG is a German biopharmaceutical company specializing in the development of therapeutic antibodies. The headcount chart reflects its transformation from a technology platform to a company with its own commercial products. The growth in headcount, particularly in the commercial department, is driven by the successful launch of new oncology drugs.
Number of employees in the market as a whole
MorphoSys AG is a German biotech company focused on developing innovative cancer treatments, which is being acquired by Novartis. The growth of its scientific and clinical staff in this chart reflects the successful advancement of its drug candidates. This team expansion is the result of years of investment in R&D, creating a valuable asset.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company MorphoSys AG (MOR)
MorphoSys AG is a German biopharmaceutical company specializing in antibodies for cancer treatment. The company's value is determined by its extensive pipeline and approved drugs. This chart shows how the market values this intellectual property portfolio. It represents the value of their patents and technologies per scientist or researcher.
%20of%20the%20company%20MorphoSys%20AG%20(MOR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-MorphoSys-AG-MOR&v=1772513492165 "Chart of market capitalization per employee (in thousands of dollars) of the company MorphoSys AG (MOR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
MorphoSys AG is a German biotech company specializing in the development of antibodies for cancer treatment. Its value is determined by its portfolio of proprietary and partnered developments. This chart shows how the market values its scientific platform and clinical program potential per research staff member.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772513492177 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
MorphoSys AG is a German biopharmaceutical company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. The chart shows the valuation of a mature biotech company. It reflects the value created by the team of scientists through both their own developments and partnerships with other pharmaceutical giants.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513492185 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company MorphoSys AG (MOR)
MorphoSys is a German biotech company (acquired by Novartis) with an approved lymphoma drug (Monjuvi) and is developing others (including Pelabresib). This chart shows the commercial and R&D efficiencies that led to its acquisition by the pharma giant.
%20Chart%20MorphoSys%20AG%20(MOR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-MorphoSys-AG-MOR&v=1772513492201 "Company Profit Per Employee (in thousands of dollars) Chart MorphoSys AG (MOR)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
MorphoSys is a German biotech company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. The company has approved drugs and an extensive development pipeline. This chart shows how effectively the company commercializes its products and invests in R&D. It serves as a benchmark for assessing the success of its scientific and commercial strategy.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772513492237 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
MorphoSys AG is a German biotech company, a leader in antibody development. The company has an approved drug for the treatment of blood cancer (Monjuvi). This chart shows how effectively the company utilizes its staff to commercialize the approved drug while simultaneously investing in R&D of new molecules.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513492264 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee MorphoSys AG (MOR)
MorphoSys AG is a German biotech company specializing in the development of antibodies for cancer treatment. This chart shows its commercialization progress. The growth in revenue per employee reflects both sales of its own drugs and royalties and payments from partners licensing its technologies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-MorphoSys-AG-MOR&v=1772513492328 "Sales chart per company employee MorphoSys AG (MOR)")
Sales per employee in the market segment - Cancer cure
MorphoSys (MOR) is a German biotech company with both an approved drug (Monjuvi) and a strong R&D portfolio (recently acquired by Novartis). This chart illustrates the hybrid model. Monjuvi royalty and sales revenue are generated by a small staff, while R&D is expensive, reducing average productivity.
Sales per employee for the market as a whole
MorphoSys AG is a German biotech company specializing in oncology. This metric reflects their maturity: the company has both R&D projects and commercial drugs (royalties). It measures how effectively their commercial assets finance future research and demonstrates the return on investment from their R&D staff and sales.
Short shares by company, segment and market as a whole
Shares shorted by company MorphoSys AG (MOR)
MorphoSys (MOR) is a German biotech company specializing in developing antibodies for cancer treatment. Their key drug targets blood cancer (lymphoma). This chart shows bearish bets. Are the bears doubting the commercial success of their drugs or the strength of their R&D platform?
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-MorphoSys-AG-MOR&v=1772513492472 "Short Shares Chart for the Company MorphoSys AG (MOR)")
Shares shorted by market segment - Cancer cure
MorphoSys AG is a German biopharmaceutical company specializing in the development of antibodies for the treatment of cancer and autoimmune diseases. This chart shows the total volume of shorts across the entire oncology biotech sector. It serves as a barometer of sentiment: if investors are short a sector, they doubt the success of new platforms or expect clinical trial failures in the industry.
Shares shorted by the overall market
MorphoSys, a cancer-focused biopharmaceutical company, needs investment for R&D. Even with approved products, research is expensive. This indicator of growing pessimism is critical, as fear is driving investors to reduce their investments in the risky biotech sector, impacting funding and valuations.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator MorphoSys AG (MOR)
MorphoSys is one of Germany's leading biotech companies, focused on oncology. This chart shows the M&A frenzy. Investor interest has peaked and plateaued. This occurred following the announcement of the company's acquisition by Swiss giant Novartis, which is targeting their promising cancer drug.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-MorphoSys-AG-MOR&v=1772513492554 "RSI 14 indicator chart for the company's stock MorphoSys AG (MOR)")
RSI 14 Market Segment - Cancer cure
MorphoSys is a biotech pioneer (Germany) in antibodies. Their focus is oncology (blood cancer), like the drug Monjuvi (acquired by Novartis). The "Cancer Cure" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: was the MorphoSys acquisition due to their R&D or the general "hype" in the sector?
RSI 14 for the overall market
For MorphoSys, a biotech company in the R&D stage, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MOR (MorphoSys AG)
MorphoSys is a German biotech company (acquired by Novartis) that developed Pelabresib for the treatment of myelofibrosis. This chart shows the average analyst forecast. Their targets were based on an assessment of Pelabresib's clinical data, its combination with Jakafi, and, finally, the Novartis acquisition price.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MOR-MorphoSys-AG&v=1772513492672 "A chart showing analyst consensus forecasts for the expected stock price. MOR (MorphoSys AG)")
The difference between the consensus estimate and the actual stock price MOR (MorphoSys AG)
MorphoSys is a German R&D titan. The biotech company has developed a powerful antibody platform, which has led to the creation of blockbusters (Tremfya) and oncology drugs. This chart shows how far the current share price differs from its "fair" value. It reflects analysts' views on their R&D and the price of their acquisition by Novartis.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MOR-MorphoSys-AG&v=1772513492693 "A chart showing the difference between the consensus forecast and the actual stock price. MOR (MorphoSys AG)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
MorphoSys (MOR) is a German biotech giant and a pioneer in antibody development. The company has both its own drugs (Monjuvi) and a robust R&D pipeline. This chart shows analysts' overall expectations for the cancer treatment sector, reflecting whether experts believe antibody-based R&D platforms will be successful.
Analysts' consensus forecast for the overall market share price
MorphoSys (MOR) is a pioneering German biotech company. They developed a platform for creating therapeutic antibodies, which led to the creation of blockbuster cancer treatments (like Monjuvi). This chart shows the overall risk appetite. It reflects how much investors value mature R&D platforms that have proven their worth (the company was acquired by Novartis).
AKIMA index of the company, segment and market as a whole
AKiMA Company Index MorphoSys AG
MorphoSys is a German antibody pioneer. Their signature feature is their R&D platform (HuCAL) for creating new drugs (antibodies). Their business is driven by two engines: royalties (from drugs sold to partners, like Tremfya) and in-house R&D (for blood cancer, Pelabresib). This chart is a summary indicator of their R&D machine. It reflects their (growing) royalties and their (risky) pipeline.
AKIMA Market Segment Index - Cancer cure
MorphoSys (MOR) is a German cancer treatment company. It's a biotech company that has developed and is partnering with a company to market a blood cancer treatment and has a robust R&D portfolio. This chart compares their composite index to the oncology sector average.
The AKIM Index for the overall market
MorphoSys is a German biotech company specializing in cancer treatment (Pelabresib). It was acquired by Novartis. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this mature European biopharma stacked up against overall economic trends before the acquisition.
